Cancer / Oncology
NCCN and Vietnam Partners Expand Cancer Guideline Collaboration to Include Lymphomas and Thyroid Cancer
NCCN and Viet Nam National Cancer Hospital sign agreement to enhance ongoing guideline adaptation efforts with the inclusion of additional hematologic...
November 06, 2026 | News
Akeso’s Ivonescimab Plus Chemotherapy Granted Priority Review in China for First-Line Biliary Tract Cancer
Akeso, Inc. announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer...
November 06, 2026 | News
Pierre Fabre Launches BRAFTOVI–MEKTOVI Combination for BRAF-Mutant Lung Cancer in Singapore
New targeted treatment option now available in for adult patients with BRAFV600E mutant advanced non-small cell lung cancer (NSCLC) Launch follows Europ...
November 04, 2026 | News
Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...
November 02, 2026 | News
Kelun-Biotech Secures China NMPA Review for Sac-TMT and Pembrolizumab Combination in First-Line Lung Cancer
This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen o...
October 29, 2026 | News
Innovent Seeks China Approval for Sintilimab and Nolgileucel Combination in Advanced Melanoma
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
October 28, 2026 | News
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
October 26, 2026 | News
Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer
Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...
October 23, 2026 | News
Geneos Launches Global Phase 2 Trial of Personalised Cancer Vaccine to Prevent Liver Cancer Recurrence
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), a...
October 23, 2026 | News
Therakos Secures EU MDR Approval for First-of-Its-Kind Therapy to Manage Cancer Immunotherapy Toxicities
Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced t...
October 23, 2026 | News
Telix and Ekalia Join Forces to Scale Astatine-211 Production for Next-Generation Cancer Therapies in the US
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with signific...
October 20, 2026 | News
SOPHiA GENETICS, Myriad Genetics and AstraZeneca Collaborate to Advance Precision Oncology in Prostate Cancer
SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) announce a collaboration to advance new prostate cancer-specific genomi...
October 13, 2026 | News
12 APAC-Originated Programmes to Watch at ESMO 2026
When the ESMO Congress 2026 opens at IFEMA Madrid on Friday 23 October, the region that most European oncologists still think of as a fast follower will ho...
October 13, 2026 | News
Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) ev...
October 12, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
